Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)

NCT05263206 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

284

Enrollment

INDUSTRY

Sponsor class

Conditions

Pruritus

Interventions

DRUG: Dupilumab
DRUG: Placebo
DRUG: Fexofenadine (loratadine if not available)

Sponsor

Sanofi